Olutasidenib Approved for IDH1-Mutated Acute Myeloid Leukemia

December 02, 2022

The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.

Ponatinib Outperforms Imatinib in Newly Diagnosed Philadelphia Chromosome+ Acute Lymphoblastic Leukemia

November 27, 2022

Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.